Related Experiment Video

Updated: Jan 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K

The Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Cardiovascular Outcomes in Heart Failure: A Systematic

Akshay Maharaj1, Sajay Bidhesi2, Diya Grover3

  • 1Internal Medicine, Port of Spain General Hospital, Port of Spain, TTO.

Cureus
|January 1, 2026
PubMed

Insights

Sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce mortality and rehospitalization in heart failure patients. These findings highlight SGLT2 inhibitors as a valuable therapeutic option for improving cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally for type 2 diabetes, exhibit cardioprotective and renoprotective effects.
  • Heart failure (HF) is a major cause of morbidity and mortality, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the impact of SGLT2 inhibitors on heart failure outcomes.
  • To assess the effects of SGLT2 inhibitors on HF hospitalizations, mortality, renal function, and left ventricular ejection fraction (LVEF).

Main Methods:

  • Systematic review and meta-analysis of nine large randomized controlled trials (RCTs).
  • Pooled risk ratios were calculated using a random-effects model to summarize overall treatment effects.

Main Results:

  • SGLT2 inhibitors demonstrated a 20% relative reduction in mortality (RR = 0.80).
  • A 24% relative risk reduction in rehospitalization due to heart failure was observed (RR = 0.76).
  • Benefits were consistent across diverse patient subgroups.

Conclusions:

  • SGLT2 inhibitors offer significant cardioprotective benefits in heart failure management.
  • These agents effectively reduce heart failure-related hospitalizations and mortality.
  • SGLT2 inhibitors represent a valuable therapeutic option for a broad range of heart failure patients.
Keywords:
cardiology researchcardiovascular diseasedapagliflozinempagliflozinheart failuresodium-glucose cotransporter 2 inhibitorsystematic review and meta analysis

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559